LITTLE FALLS, N.J.,
Jan. 8, 2014 /PRNewswire/
-- CANTEL MEDICAL CORP. (NYSE: CMN), through its
Crosstex subsidiary, has further expanded its sterility assurance
monitoring business with the acquisition of Sterilator Company,
Inc. Based in Cuba, NY,
Sterilator Company is a high-quality manufacturer of biological
indicators and supplies for sterility assurance products, which are
used to accurately monitor the effectiveness of sterilization
processes. Sterilator serves both the medical and industrial
markets, and has been a long-time supplier of self-contained
biological indicators, dual species spore strips and culture media
to our dental and hospital healthcare disposable
business.
Gary Steinberg, President and CEO
of Crosstex said, "This acquisition allows us to add one of our key
long-standing suppliers of biological indicators to our portfolio,
providing a strategic benefit to our overall sterility assurance
monitoring business. I am also pleased that we will retain
Sterilator's current leadership, who will serve an integral role in
new product development and R&D initiatives in sterility
assurance."
Andrew Krakauer, President and
CEO of Cantel Medical added, "This acquisition further enhances our
capabilities as a leading provider of sterility assurance
monitoring products to the medical industry. Furthermore,
this addition strengthens our product development capabilities,
enabling Cantel to continue providing the best infection prevention
and control products and solutions to our customers."
About Cantel Medical Corp.
Cantel Medical is a leading
global company dedicated to delivering innovative infection
prevention and control products and services for patients,
caregivers, and other healthcare providers which improve outcomes,
enhance safety and help save lives. Our products include
specialized medical device reprocessing systems for endoscopy and
renal dialysis, advanced water purification equipment, sterilants,
disinfectants and cleaners, sterility assurance monitoring products
for hospitals and dental clinics, disposable infection control
products primarily for dental and GI endoscopy markets, dialysate
concentrates, hollow fiber membrane filtration and separation
products, and specialty packaging for infectious and biological
specimens. Additionally, we provide technical service for our
products. For further information, visit the Cantel website
at www.cantelmedical.com.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements involve a number of risks and uncertainties,
including, without limitation, the risks detailed in Cantel's
filings and reports with the Securities and Exchange Commission.
Such forward-looking statements are only predictions, and actual
events or results may differ materially from those projected or
anticipated.
SOURCE Cantel Medical Corp.